Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Epithelioid Hemangioendothelioma
NCT03148275Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in epithelioid hemangioendothelioma (EHE), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started Jun 2017; status: completed.
02
Drugs
trametinib
03
Conditions
epithelioid hemangioendothelioma (EHE)
Beyond the preview
Go deeper on NCT03148275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148275.